Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept extension in MDS
NCT02268383Phase 2Completed
- Start
- Oct 2014
- Primary completion
- Mar 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS). Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 5 years and Number of Participants Who Discontinued Study Treatment Due to an AE up to 5 years. Started Oct 2014; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02268383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268383.